TGen's platform.org social media study has been named a finalist for an international award honoring significant social impact
The Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based non-profit organization, has been named a finalist for the prestigious CLASSY Awards. This annual social impact celebration recognizes champions of social progress, and the winners are determined by the CLASSY Leadership Council on Health, a panel of experts from various fields.
TGen's research focuses on the translational process, which aims to rapidly move research towards patient benefit. One of TGen's current projects is the platform.org, an innovative social-media investigation of Alzheimer's disease. This web-based scientific study is called "Alzheimer's Disease Center Dataset 1" (ADC1), a GWAS-based project aiming to develop a predictive framework for Alzheimer's disease and related dementias.
The goal of TGen's platform.org is to better understand brain learning and memory processes to develop a better-informed cure for Alzheimer's. The study uses machine learning and advanced statistical modeling on diverse data types—demographics, neuropsychological measures, biofluid and imaging biomarkers—from multiple cohorts and concluded clinical trials. TGen aims to gather results from as many as 1 million participants for their platform.org study.
Alzheimer's disease is a significant socioeconomic issue, affecting over 5 million Americans, being the 6th leading cause of death in the U.S., and costing the nation over $200 billion annually to treat. The disease has proven challenging to cure due to the clinical variations among patients that have hindered success in randomized clinical trials. By integrating expert knowledge and large datasets, TGen's study seeks to identify more clinically relevant subtypes of Alzheimer's, which could lead to improved clinical outcomes and personalized therapies.
The CLASSY Awards ceremony will take place from May 2-3, 2014, in San Diego. Top leaders from the social sector will convene at the event to collaborate on solving social problems. The Translational Genomics Research Institute (TGen) platform.org is one of the finalists for the awards, and the winners will be announced during the ceremony.
TGen collaborates with scientists and physicians from around the world to contribute substantially to patient care. The lead researcher for TGen's platform.org project is an Associate Professor in TGen's Neurogenomics Division. For more information about TGen, visit www.tgen.org. Steve Yozwiak, TGen's Senior Science Writer, can be reached at [email protected] or 602-343-8704.
For those interested in participating in TGen's platform.org study, more information can be found on the TGen website. However, the article does not provide information about how to opt out or the privacy policy mentioned in the text.
In conclusion, TGen's platform.org project is an exciting development in the fight against Alzheimer's disease. By harnessing the power of big data and collaboration, TGen hopes to make significant strides in understanding the disease and finding a cure. The CLASSY Awards ceremony will be a celebration of TGen's contributions to social progress and a recognition of their work as a finalist for the awards.
- The Translational Genomics Research Institute (TGen), a finalist for the prestigious CLASSY Awards, is employing neurogenomics and scientific research to tackle Alzheimer's disease, a significant mental health issue that affects over 5 million Americans and costs the nation over $200 billion annually.
- The TGen's platform.org project, a GWAS-based study on Alzheimer's disease and related dementias, aims to develop a predictive framework and better understand brain learning and memory processes for a better-informed cure, by gathering data from as many as 1 million participants via advanced statistical modeling and machine learning.
- TGen, collaborating with scientists and physicians globally, is also focusing on identifying clinically relevant subtypes of neurogenuclal disorders like Alzheimer's to lead to improved clinical outcomes and personalized therapies, demonstrating their commitment to medical-conditions and health-and-wellness sector through research and innovation.
